Oncternal Therapeutics Coverage Initiated by StockNews.com

On December 8, 2024, StockNews.com announced the initiation of coverage on shares of Oncternal Therapeutics (NASDAQ:ONCT) through a research report. In this document, the brokerage assigned a hold rating to the stock, indicating a cautious stance on the company’s performance.

In addition to StockNews.com, other analysts have also provided updates regarding Oncternal Therapeutics. For instance, HC Wainwright lowered their price target for the company from $19.00 to $18.00 while maintaining a buy rating in a report released on Monday, August 12. Meanwhile, Northland Capital Markets downgraded the stock from a strong-buy to a hold rating in a report dated Thursday, September 12. On the same day, Brookline Capital Management reiterated a hold rating on Oncternal Therapeutics shares. Furthermore, Northland Securities re-emphasized a market perform rating with a price target of $2.00, also in a report on Thursday, September 12.

Overall, four analysts currently rate the stock as a hold, while one has given it a buy rating. According to MarketBeat, the average rating for Oncternal Therapeutics stands at hold, with a consensus price target estimated at $10.00.

Oncternal Therapeutics Stock Performance

As of Thursday, shares of NASDAQ:ONCT opened at $0.53. The company's 50-day moving average sits at $1.20, and its 200-day moving average is recorded at $4.34. With a market capitalization of approximately $1.56 million, Oncternal Therapeutics has a P/E ratio of -0.05 and a beta of 1.18. The stock has experienced substantial fluctuations, with a 52-week low of $0.53 and a high of $13.14.

Institutional Inflows and Outflows

Recent trading activities show that a hedge fund made a notable investment in Oncternal Therapeutics. Pasadena Private Wealth LLC acquired a new stake in the company, purchasing 25,000 shares in the second quarter, valued at around $190,000 according to their 13F filing with the Securities and Exchange Commission. This investment reflects that Pasadena Private Wealth LLC held about 0.84% of Oncternal Therapeutics shares at the end of the latest quarter. Currently, institutional investors make up 16.05% of the company’s stock ownership.

About Oncternal Therapeutics

Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company that is dedicated to developing innovative oncology therapies targeting cancers with significant unmet medical needs. The company’s clinical pipeline features zilovertamab, a humanized monoclonal antibody that binds to receptor-tyrosine kinase-like orphan receptor 1 (ROR1), as well as ONCT-216, a small molecule that inhibits the activity of ETS-family transcription factor oncoproteins; ONCT-216 is currently in Phase 1/2 clinical trials.

Oncternal, Therapeutics, analysts